{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:03:43Z","timestamp":1780074223361,"version":"3.54.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271735"],"award-info":[{"award-number":["82271735"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12519-026-01039-0","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:49:19Z","timestamp":1778525359000},"page":"483-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-symptomatic treatment of spinal muscular atrophy: a strategic shift from concept to clinical practice"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-1407","authenticated-orcid":false,"given":"Shan-Shan","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"1039_CR1","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41467-025-67725-1","volume":"17","author":"I Faravelli","year":"2025","unstructured":"Faravelli I, Rinchetti P, Tambalo M, Simutin I, Mapelli L, Mancinelli S, et al. Targeted antisense oligonucleotide treatment rescues developmental alterations in spinal muscular atrophy organoids. Nat Commun. 2025;17:988. https:\/\/doi.org\/10.1038\/s41467-025-67725-1.","journal-title":"Nat Commun"},{"key":"1039_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Prim. 2022;8:52. https:\/\/doi.org\/10.1038\/s41572-022-00380-8.","journal-title":"Nat Rev Dis Prim"},{"key":"1039_CR3","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1007\/s12035-017-0831-9","volume":"55","author":"A Govoni","year":"2018","unstructured":"Govoni A, Gagliardi D, Comi GP, Corti S. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol. 2018;55:6307\u201318. https:\/\/doi.org\/10.1007\/s12035-017-0831-9.","journal-title":"Mol Neurobiol"},{"key":"1039_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/ijns10030056","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, et al. Systematic review of presymptomatic treatment for spinal muscular atrophy. Int J Neonatal Screen. 2024;10:56. https:\/\/doi.org\/10.3390\/ijns10030056.","journal-title":"Int J Neonatal Screen"},{"key":"1039_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2025.105585","volume":"53","author":"N Kuntz","year":"2025","unstructured":"Kuntz N, De Vivo D, Crawford T, Kirschner J, Finkel R, Bertini E, et al. 422P NURTURE study: long-term benefits of nusinersen in presymptomatic spinal muscular atrophy (SMA) over 8 years of follow-up. Neuromuscul Disord. 2025;53:105585. https:\/\/doi.org\/10.1016\/j.nmd.2025.105585.","journal-title":"Neuromuscul Disord"},{"key":"1039_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJMoa2410120","volume":"393","author":"RS Finkel","year":"2025","unstructured":"Finkel RS, Servais L, Vlodavets D, Zanoteli E, Mazurkiewicz-Be\u0142dzi\u0144ska M, Jong YJ, et al. Risdiplam in presymptomatic spinal muscular atrophy. N Engl J Med. 2025;393:671\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2410120.","journal-title":"N Engl J Med"},{"key":"1039_CR7","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med. 2022;28:1390\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01867-3.","journal-title":"Nat Med"},{"key":"1039_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ped4.70003","volume":"9","author":"Z Sun","year":"2025","unstructured":"Sun Z, Wu L, Hui Y, Zhong Y, Yang J, Sun Z, et al. Pre-symptomatic risdiplam treatment for spinal muscular atrophy initiated at 12 days post-birth: 14-month safety and developmental outcomes. Pediatr Investig. 2025;9:201\u20132. https:\/\/doi.org\/10.1002\/ped4.70003.","journal-title":"Pediatr Investig."},{"key":"1039_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200310","volume":"14","author":"M Schroth","year":"2024","unstructured":"Schroth M, Deans J, Arya K, Castro D, De Vivo DC, Gibbons MA, et al. Spinal muscular atrophy update in best practices: recommendations for diagnosis considerations. Neurol Clin Pract. 2024;14:e200310. https:\/\/doi.org\/10.1212\/CPJ.0000000000200310.","journal-title":"Neurol Clin Pract."},{"key":"1039_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejpn.2024.06.001","volume":"51","author":"J Kirschner","year":"2024","unstructured":"Kirschner J, Bernert G, Butoianu N, De Waele L, Fattal-Valevski A, Haberlova J, et al. 2024 update: European consensus statement on gene therapy for spinal muscular atrophy. Eur J Paediatr Neurol. 2024;51:73\u20138. https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.001.","journal-title":"Eur J Paediatr Neurol"},{"key":"1039_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/22143602241288095","volume":"11","author":"E Vr\u0161\u010daj","year":"2024","unstructured":"Vr\u0161\u010daj E, Dangouloff T, Osredkar D, Servais L, SMA NBS World Study Group. Newborn screening programs for spinal muscular atrophy worldwide in 2023. J Neuromuscul Dis. 2024;11:1180\u20139. https:\/\/doi.org\/10.1177\/22143602241288095.","journal-title":"J Neuromuscul Dis."},{"key":"1039_CR12","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s12519-024-00846-7","volume":"20","author":"C Chen","year":"2024","unstructured":"Chen C, Zhang C, Wu DW, Wang BY, Xiao R, Huang XL, et al. Comprehensive newborn screening for severe combined immunodeficiency, X-linked agammaglobulinemia, and spinal muscular atrophy: the Chinese experience. World J Pediatr. 2024;20:1270\u201382. https:\/\/doi.org\/10.1007\/s12519-024-00846-7.","journal-title":"World J Pediatr."},{"key":"1039_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/ijns10030049","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, et al. Systematic review of newborn screening programmes for spinal muscular atrophy. Int J Neonatal Screen. 2024;10:49. https:\/\/doi.org\/10.3390\/ijns10030049.","journal-title":"Int J Neonatal Screen."},{"key":"1039_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3760\/cma.j.cn511734-20231115-00256","volume":"41","author":"T Hu","year":"2024","unstructured":"Hu T, Guo J, Liu S, Lu Y, Chang Q, Consensus Expert Group on Carrier Screening for Monogenic Disorders, Genetic Counseling Group of Medical Genetics Branch of Chinese Medical Association. Expert consensus over genetic counseling for carrier screening of spinal muscular atrophy. Chin J Med Genet. 2024;41:661\u20138. https:\/\/doi.org\/10.3760\/cma.j.cn511734-20231115-00256.","journal-title":"Chin J Med Genet."},{"key":"1039_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.12372\/jcp.2025.25e0953","volume":"43","author":"Clinical Epidemiology Group of Chinese Pediatrics Society of Chinese Medical Association; Screening Group of Neonatal Genetic Metabolic Disease, Special Committee of Birth Defects Prevention and Control, Chinese Preventive Medical Association; Society for Neuroscience and Neurology, Chinese Research Hospital Association; Meier Advocacy & Support Center for SMA","year":"2025","unstructured":"Clinical Epidemiology Group of Chinese Pediatrics Society of Chinese Medical Association; Screening Group of Neonatal Genetic Metabolic Disease, Special Committee of Birth Defects Prevention and Control, Chinese Preventive Medical Association; Society for Neuroscience and Neurology, Chinese Research Hospital Association; Meier Advocacy & Support Center for SMA. Expert consensus on pre-symptomatic treatment for pediatric spinal muscular atrophy (2025 edition). J Clin Pediatr. 2025;43:643\u201351. https:\/\/doi.org\/10.12372\/jcp.2025.25e0953.","journal-title":"J Clin Pediatr"},{"key":"1039_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2025.10.018","author":"WC Weng","year":"2025","unstructured":"Weng WC, Lee WT, Chien YH, Tsai LK. Updates of spinal muscular atrophy in advanced therapies. J Formos Med Assoc. 2025. https:\/\/doi.org\/10.1016\/j.jfma.2025.10.018.","journal-title":"J Formos Med Assoc"},{"key":"1039_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200374","volume":"15","author":"MK Schroth","year":"2025","unstructured":"Schroth MK, Deans J, Bharucha Goebel DX, Burnette WB, Darras BT, Elsheikh BH, et al. Spinal muscular atrophy update in best practices: recommendations for treatment considerations. Neurol Clin Pract. 2025;15:e200374. https:\/\/doi.org\/10.1212\/CPJ.0000000000200374.","journal-title":"Neurol Clin Pract."},{"key":"1039_CR18","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00415-024-12188-5","volume":"271","author":"K Vill","year":"2024","unstructured":"Vill K, Tacke M, K\u00f6nig A, Baumann M, Baumgartner M, Steinbach M, et al. 5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of  SMN2 . J Neurol. 2024;271:2787\u201397. https:\/\/doi.org\/10.1007\/s00415-024-12188-5.","journal-title":"J Neurol"},{"key":"1039_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00415-025-13314-7","volume":"272","author":"S Corti","year":"2025","unstructured":"Corti S, Ottoboni L, Sansone V. Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time. J Neurol. 2025;272:605. https:\/\/doi.org\/10.1007\/s00415-025-13314-7.","journal-title":"J Neurol"},{"key":"1039_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","volume":"23","author":"WC Weng","year":"2021","unstructured":"Weng WC, Hsu YK, Chang FM, Lin CY, Hwu WL, Lee WT, et al. CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening. Genet Med. 2021;23:415\u201320. https:\/\/doi.org\/10.1038\/s41436-020-00987-w.","journal-title":"Genet Med"},{"key":"1039_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1515\/cclm-2023-1311","volume":"62","author":"S Bayoumy","year":"2024","unstructured":"Bayoumy S, Verberk IMW, Vermunt L, Willemse E, den Dulk B, van der Ploeg AT, et al. Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges. Clin Chem Lab Med. 2024;62:1252\u201365. https:\/\/doi.org\/10.1515\/cclm-2023-1311.","journal-title":"Clin Chem Lab Med"},{"key":"1039_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/mus.70155","volume":"73","author":"J Jin","year":"2026","unstructured":"Jin J, Feng Y, Yu Y, Jiang L, Ren J, Zou X, et al. Plasma neurofilament light chain as a potential biomarker of presymptomatic spinal muscular atrophy. Muscle Nerve. 2026;73:635\u201340. https:\/\/doi.org\/10.1002\/mus.70155.","journal-title":"Muscle Nerve"},{"key":"1039_CR23","doi-asserted-by":"publisher","first-page":"7S45","DOI":"10.1016\/S0929-693X(20)30277-3","volume":"27","author":"J Ropars","year":"2020","unstructured":"Ropars J, Peudenier S, Genot A, Barnerias C, Espil C. Multidisciplinary approach and psychosocial management of spinal muscular atrophy (SMA). Arch Pediatr. 2020;27:7S45-9. https:\/\/doi.org\/10.1016\/S0929-693X(20)30277-3.","journal-title":"Arch Pediatr"},{"key":"1039_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mus.28468","volume":"72","author":"C Wozow","year":"2025","unstructured":"Wozow C, Mosher K. Transitions from pediatric to adult neuromuscular care: a practical guide. Muscle Nerve. 2025;72:558\u201365. https:\/\/doi.org\/10.1002\/mus.28468.","journal-title":"Muscle Nerve"},{"key":"1039_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.005.","journal-title":"Neuromuscul Disord"},{"key":"1039_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197\u2013207. https:\/\/doi.org\/10.1016\/j.nmd.2017.11.004.","journal-title":"Neuromuscul Disord"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01039-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-026-01039-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-026-01039-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:15:59Z","timestamp":1780071359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-026-01039-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s12519-026-01039-0","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}